TY  - JOUR
T1  - SCreening and detection of breast cancer and prostate cancer
AU  - Paneth N, Vande Woude G, Kort E
Y1  - 2010/03/17
N1  - 10.1001/jama.2010.274
JO  - JAMA
SP  - 1032
EP  - 1034
VL  - 303
IS  - 11
N2  - 
The relative age-adjusted decline in US prostate cancer mortality from 38.2 per 100 000 men in 19942 (shortly after the introduction of prostate-specific antigen [PSA] screening) to 23.5 per 100 000 men in 20063 is nearly 40%, about 3% per year. It is not clear to us what factor or factors other than PSA screening could be driving this decline.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.274
UR  - http://dx.doi.org/10.1001/jama.2010.274
ER  -